Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis–A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis–A systematic review and network meta-analysis

Published:2021-04 Issue: Volume:49 Page:102769
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Bartosik-Psujek Halina,Kaczyński Łukasz,Górecka Magdalena,Rolka Mirosław^ORCID,Wójcik Rafał,Zięba Patrycja,Kaczor Marcin

Funder

Merck

Merck KGaA

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference40 articles.

1. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014

2. Efficacy of teriflunomide treatment in achieving no evidence of disease activity over a period of 6 months to 2 years in the TEMSO study;Chan;Mult. Scler. J.,2015

3. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis;Comi;Expert Opin. Pharmacother.,2013

4. Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod;Diem;Ther. Adv. Neurol. Disord.,2018

5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis;Fox;N. Engl. J. Med.,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05

2. Practical Guidance on the Use of Cladribine Tablets in the Management or Relapsing Multiple Sclerosis: Expert Opinion from Qatar;Degenerative Neurological and Neuromuscular Disease;2023-12

3. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis;Neurological Sciences;2023-04-17

4. Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment;Journal of Neurology;2023-03-13

5. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study;Multiple Sclerosis and Related Disorders;2023-02